Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 51817-586

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 51817-586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmascience Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (Carton)

Bortezomib for Injection 3.5 mg/vial powder, lyophilized, for intravenous or subcutaneous use. The label displays reconstitution instructions with specified amounts of diluent for subcutaneous and intravenous administration. The product is labeled as a single dose vial with unused portion to be discarded, manufactured by Pharmascience Inc., NDC 51817-586-01.*

FDA Label Image

Bortezomib Chemical Structure (Chemical Structure)

Chemical structure diagram of bortezomib, the active ingredient in the injectable lyophilized powder form for intravenous or subcutaneous use by Pharmascience Inc.*

FDA Label Image

Graph (Time to progression)

A Kaplan-Meier survival curve showing the percentage of patients over time in months. The graph compares two groups labeled Vc-MP and MP, with Vc-MP represented by a red line indicating higher patient survival percentages over time compared to MP in blue. Below the graph, a table lists the number of patients at risk at several time points for both groups. The p-value from the log-rank test is noted as 0.000002, indicating statistical significance between the groups.*

FDA Label Image

Graph (Overall survival)

A Kaplan-Meier survival curve comparing percentage of patients over time (in months) between two treatment groups labeled Vc-MP and MP. The X-axis represents time in months up to 78, and the Y-axis shows percentage of patients from 0 to 100%. The chart includes numbers of patients at risk at various time points for both groups, with Vc-MP having consistently higher survival percentages than MP. A p-value less than 0.05 from a log-rank test is noted.*

FDA Label Image

Graph (Time to progression)

A survival curve chart comparing the proportion of patients over time (days) treated with Bortezomib and Dexamethasone. The y-axis shows the proportion of patients, starting at 1.0, and the x-axis shows time in days up to 480. Bortezomib data is represented with blue circles and a solid line, while Dexamethasone data is shown with red crosses and a dashed line. Patient numbers remaining at different time points are noted below the x-axis, and the chart includes a p-value indication from a log-rank test (p < 0.0001).*

FDA Label Image

Graph (Overall survival)

A survival curve graph comparing the proportion of patients over time (days) receiving Bortezomib versus Dexamethasone. The vertical axis represents the proportion of patients, starting at 1.0, and the horizontal axis represents time in days up to 450. Two curves are shown: one labeled Bortezomib with blue circles and the other Dexamethasone with red crosses, indicating patient survival decline over time. Below the x-axis is a table showing the number of patients remaining at specific time points for each treatment group. Statistical significance is noted with a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Progression Free Survival (Figure5)

A Kaplan-Meier survival curve graph showing the percentage of patients over time (in months) for two treatment groups, labeled VcR-CAP and R-CHOP. The y-axis represents the percentage of patients, and the x-axis represents time in months up to 60 months. The chart includes numbers of subjects at risk for each group at different time points and notes a log rank test p-value of less than 0.001.*

FDA Label Image

Overall Survival (Figure6)

A Kaplan-Meier survival curve illustrating the percentage of subjects alive over time (months) from randomization. Two treatment groups, VcR-CAP (solid line) and R-CHOP (dashed line), are compared with associated numbers of subjects at risk given at various time points. A hazard ratio with 95% confidence interval (0.66, 0.51 to 0.85) is displayed on the graph.*

FDA Label Image

Vial Label (Vial)

Bortezomib injection powder, lyophilized, 3.5 mg per vial, single dose vial with discard unused portion instruction. Label indicates use for intravenous or subcutaneous administration. The labeler is Pharmascience Inc. and the package shows NDC 51817-586-01. Barcode and storage instructions are visible, with lot and expiration date fields.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.